Evidence map›Paper›PMID 34522592›Full record

ReviewActa pharmaceutica Sinica. B2021

A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives.

Yujie Shi, An Lu, Xiangyu Wang, Zakia Belhadj, Jiancheng Wang, Qiang Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Progressive microneedles for targeting and intelligent drug delivery.Asian journal of pharmaceutical sciences · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Strategies for long-acting drug design.Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Review
  12. Review
  13. IL-1 receptor antagonist: etiological and drug delivery systems overview.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Journal of the American Chemical Society · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yujie ShiBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
An LuBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Xiangyu WangBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Zakia BelhadjBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Jiancheng WangBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Qiang ZhangBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The need for long-term treatments of chronic diseases has motivated the widespread development of long-acting parenteral formulations (LAPFs) with the aim of improving drug pharmacokinetics and therapeutic efficacy. LAPFs have been proven to extend the half-life of therapeutics, as well as to improve patient adherence; consequently, this enhances the outcome of therapy positively. Over past decades, considerable progress has been made in designing effective LAPFs in both preclinical and clinical settings. Here we review the latest advances of LAPFs in preclinical and clinical stages, focusing on the strategies and underlying mechanisms for achieving long acting. Existing strategies are classified into manipulation of

Indexed as

2′-F, 2′-fluoro2′-OMe, 2′-O-methyl2′-O-MOE, 2′-O-(2-methoxyethyl)3D, three-dimensionalART, antiretroviral therapyASO, antisense oligonucleotideBiomimetic strategiesChemical modificationDDS, drug delivery systemsECM, extracellular matrixENA, ethylene-bridged nucleic acidESC, enhanced stabilization chemistryEVA, ethylene vinyl acetateFc/HSA fusionFcRn, Fc receptorGLP-1, glucagon like peptide-1GS, glycine–serineHA, hyaluronic acidHES, hydroxy-ethyl-starchhGH, human growth hormoneHP, hypoparathyroidismHSA, human serum albuminHydrogelsIgG, immunoglobulin Gim, intramuscularImplantable systemsISFI, in situ forming implantsiv, intravenousLAFs, long-acting formulationsLAPFs, long-acting parenteral formulationsLNA, locked nucleic acidLong-actingMicroneedlesMNs, microneedlesmPEG, methoxypolyethylene glycolNanocrystal suspensionsNDS, nanochannel delivery systemNPs, nanoparticlesOA, osteoarthritisPCPP-SA, poly(1,3-bis(carboxyphenoxy)propane-co-sebacic-acid)PEG, polyethylene glycolPMPC, poly(2-methyacryloyloxyethyl phosphorylcholine)PM, platelet membranePNAs, peptide nucleic acidsPSA, polysialic acidPS, phase separationPTH, parathyroid hormonePVA, polyvinyl alcoholRBCs, red blood cellsRES, reticuloendothelial systemRNAi, RNA interferenceSAR, structure‒activity relationshipSCID, severe combined immunodeficiencysc, subcutaneousSE, solvent extractionSTC, standard template chemistryTNFR2, tumor necrosis factor receptor 2

Identifiers

PMID34522592
PMCPMC8424287

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.